NCI's Reorganization, Director Scrutinized By Cancer Board

if (n == null) The Scientist - NCI's Reorganization, Director Scrutinized By Cancer Board   The Scientist 10[1]:, Jan. 08, 1996 News NCI's Reorganization, Director Scrutinized By Cancer Board By Myrna E. Watanabe Little official business was concluded at a two-day meeting of the National Cancer Advisory Board (NCAB) November 28-29. Rather, the proceedings were dominated by a lavish presentation of the wide-ranging reorganization of the National Cance

Written byMyrna Watanabe
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share


News

Little official business was concluded at a two-day meeting of the National Cancer Advisory Board (NCAB) November 28-29. Rather, the proceedings were dominated by a lavish presentation of the wide-ranging reorganization of the National Cancer Institute (NCI) and its mercurial director, Richard D. Klausner, who orchestrated the restructuring.

Klausner announced, for the first time, the "profound administrative changes" that he began to implement at NCI after he took over this position in August. He proclaimed that as of October 1, the reorganization of NCI was completed.

Richard Klausner CHANGES AFOOT: Director Richard Klausner presented NCI's "profound restructuring" to the advisory board. "Completed" may be something of an overstatement, however. As a fax from Klausner's office to The Scientist outlining the NCI organization clearly indicates-with its crossing out of branches and penciling in of names and phone numbers-the process is ongoing.

"I think these administrative changes are important," Klausner told the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies